Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Cystic Fibrosis Β· Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) Pty.

Vertex Pharmaceuticals (Australia) clinical programs β€” 159 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Official website β†— All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis β†’
Intelligence Β· Clinical Programs

Vertex Pharmaceuticals (Australia) projects

159 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).

Vertex Pharmaceuticals (Australia) has 159 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

159 programs

Clinical programs

Page 1 of 4

  1. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  2. CTX001

    Vertex Pharmaceuticals (Australia) Pty.

    Beta-Thalassemia

    phase 3 mab active

    1 trial

  3. CTX001-111

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent Ξ²-thalassemia (TDT)

    phase 3 small molecule active

    1 trial

  4. Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease, Transfusion dependent thalassemia

    phase 3 small molecule active

    1 trial

  5. ELX/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    19 trials

  6. Exa-cel

    Vertex Pharmaceuticals (Australia) Pty.

    Sickle Cell Disease

    phase 3 mab terminated

    1 trial

  7. IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  8. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    16 trials

  9. LUM

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  10. Lumacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  11. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  12. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  13. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  14. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  15. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  16. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial

  17. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  18. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  19. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  20. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  21. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  22. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 3 small molecule active

    3 trials

  23. Suzetrigine (SUZ)

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  24. TEZ

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  25. TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  26. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 3 small molecule terminated

    2 trials

  27. Tezacaftor/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  28. VNZ/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    4 trials

  29. VX-121/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    6 trials

  30. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 3 small molecule active

    1 trial

  31. VX-210

    Vertex Pharmaceuticals (Australia) Pty.

    Cervical Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial

  32. VX-445/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  33. VX-509

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  34. VX-659/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    4 trials

  35. VX-661 Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  36. VX-661/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  37. VX-809

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    4 trials

  38. VX-880

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetes Mellitus, Type 1

    phase 3 mab active

    1 trial

  39. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  40. VX20-121-104

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  41. VX20-445-112

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  42. VX21-121-105

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  43. VX21-147-301

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Proteinuric Kidney Disease (AMKD)

    phase 3 small molecule active

    1 trial

  44. VX21-445-125

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  45. VX21-CTX001-141

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-Dependent-Thalassemia

    phase 3 small molecule active

    1 trial

  46. VX21-CTX001-151

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  47. VX21-CTX001-161

    Vertex Pharmaceuticals (Australia) Pty.

    Transfusion-dependent Ξ²-thalassemia (TDT), Severe sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  48. VX22-445-122

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Vertex Pharmaceuticals (Australia) have?

159 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.